Cargando…
The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
Introduction. Despite a successful percutaneous coronary intervention (PCI), several studies reported that the recurrence of angina after revascularization, even complete, is a particularly frequent occurrence in the first year after PCI. Methods. The aim was to evaluate the efficacy of treatment wi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408663/ https://www.ncbi.nlm.nih.gov/pubmed/32635532 http://dx.doi.org/10.3390/jcm9072110 |
_version_ | 1783567883422400512 |
---|---|
author | Calcagno, Simone Infusino, Fabio Salvi, Nicolò Taccheri, Temistocle Colantonio, Riccardo Bruno, Emanuele Birtolo, Lucia Ilaria Severino, Paolo Lavalle, Carlo Pucci, Mariateresa Sardella, Gennaro Mancone, Massimo Fedele, Francesco |
author_facet | Calcagno, Simone Infusino, Fabio Salvi, Nicolò Taccheri, Temistocle Colantonio, Riccardo Bruno, Emanuele Birtolo, Lucia Ilaria Severino, Paolo Lavalle, Carlo Pucci, Mariateresa Sardella, Gennaro Mancone, Massimo Fedele, Francesco |
author_sort | Calcagno, Simone |
collection | PubMed |
description | Introduction. Despite a successful percutaneous coronary intervention (PCI), several studies reported that the recurrence of angina after revascularization, even complete, is a particularly frequent occurrence in the first year after PCI. Methods. The aim was to evaluate the efficacy of treatment with ranolazine in addition to conventional anti-ischemic therapy in patients who underwent coronary angiography for persistent/recurrent angina after PCI and residual ischemia only due to small branches not suitable for further revascularization. Forty-nine consecutive patients were included in our registry, adding the ranolazine (375 mg b.i.d) to optimal medical therapy (OMT). The Exercise ECG Test (EET) was performed in all patients before to start the therapy (baseline BL) and at 30 days (T1) after enrollment. Results. The average duration of the exercise was increased after the therapy with ranolazine comparing to baseline (RG 9’1” ± 2’ versus BL 8’10” ± 2’, p = 0.01). Seven (14.3%) patients after receiving ranolazine had not crossed the threshold of six minutes (75 watts) compared to 20 (40.8%) of BL (p = 0.0003). Stress angina appeared more frequently at BL than at 30 days (T1 4.1% versus BL 16.3%, p = 0.04) as well as exercise-induced arrhythmias (BL 30.6% versus T1 14.3%, p = 0.05). Conclusions. The addition of ranolazine to standard anti-ischemic therapy showed a significant improvement in EET results after one month of therapy, including reduced exercise angina, increased exercise tolerance, and reduced exercise arrhythmias. |
format | Online Article Text |
id | pubmed-7408663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74086632020-08-13 The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization Calcagno, Simone Infusino, Fabio Salvi, Nicolò Taccheri, Temistocle Colantonio, Riccardo Bruno, Emanuele Birtolo, Lucia Ilaria Severino, Paolo Lavalle, Carlo Pucci, Mariateresa Sardella, Gennaro Mancone, Massimo Fedele, Francesco J Clin Med Article Introduction. Despite a successful percutaneous coronary intervention (PCI), several studies reported that the recurrence of angina after revascularization, even complete, is a particularly frequent occurrence in the first year after PCI. Methods. The aim was to evaluate the efficacy of treatment with ranolazine in addition to conventional anti-ischemic therapy in patients who underwent coronary angiography for persistent/recurrent angina after PCI and residual ischemia only due to small branches not suitable for further revascularization. Forty-nine consecutive patients were included in our registry, adding the ranolazine (375 mg b.i.d) to optimal medical therapy (OMT). The Exercise ECG Test (EET) was performed in all patients before to start the therapy (baseline BL) and at 30 days (T1) after enrollment. Results. The average duration of the exercise was increased after the therapy with ranolazine comparing to baseline (RG 9’1” ± 2’ versus BL 8’10” ± 2’, p = 0.01). Seven (14.3%) patients after receiving ranolazine had not crossed the threshold of six minutes (75 watts) compared to 20 (40.8%) of BL (p = 0.0003). Stress angina appeared more frequently at BL than at 30 days (T1 4.1% versus BL 16.3%, p = 0.04) as well as exercise-induced arrhythmias (BL 30.6% versus T1 14.3%, p = 0.05). Conclusions. The addition of ranolazine to standard anti-ischemic therapy showed a significant improvement in EET results after one month of therapy, including reduced exercise angina, increased exercise tolerance, and reduced exercise arrhythmias. MDPI 2020-07-04 /pmc/articles/PMC7408663/ /pubmed/32635532 http://dx.doi.org/10.3390/jcm9072110 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Calcagno, Simone Infusino, Fabio Salvi, Nicolò Taccheri, Temistocle Colantonio, Riccardo Bruno, Emanuele Birtolo, Lucia Ilaria Severino, Paolo Lavalle, Carlo Pucci, Mariateresa Sardella, Gennaro Mancone, Massimo Fedele, Francesco The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization |
title | The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization |
title_full | The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization |
title_fullStr | The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization |
title_full_unstemmed | The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization |
title_short | The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization |
title_sort | role of ranolazine for the treatment of residual angina beyond the percutaneous coronary revascularization |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408663/ https://www.ncbi.nlm.nih.gov/pubmed/32635532 http://dx.doi.org/10.3390/jcm9072110 |
work_keys_str_mv | AT calcagnosimone theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT infusinofabio theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT salvinicolo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT taccheritemistocle theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT colantonioriccardo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT brunoemanuele theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT birtololuciailaria theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT severinopaolo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT lavallecarlo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT puccimariateresa theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT sardellagennaro theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT manconemassimo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT fedelefrancesco theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT calcagnosimone roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT infusinofabio roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT salvinicolo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT taccheritemistocle roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT colantonioriccardo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT brunoemanuele roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT birtololuciailaria roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT severinopaolo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT lavallecarlo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT puccimariateresa roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT sardellagennaro roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT manconemassimo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization AT fedelefrancesco roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization |